Ucb Inc Drug Patent Portfolio

Ucb Inc's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Ucb Inc News

Unprecedented number of FDA biosimilar approvals opens doors for pharmaceutical developers.

20 May, 2025

FDA Approval Granted for J&J's Autoimmune Treatment Marks the First of Several Anticipated for the Promising Drug

01 May, 2025

Three new FDA approvals quickly enhance Bimzelx's potential for success at UCB

23 Sep, 2024

UCB aims to expand use of psoriasis medication Bimzelx with four new indications in 2024 to achieve success similar to a blockbuster.

28 Feb, 2024

See More